Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Contrarian Investing -- Ignore unavailable to you. Want to Upgrade?

To: pcyhuang who wrote (240)	9/18/2006 9:32:06 PM
From: Biomaven	Respond to of 4080

From that article: Biovail is taking legal action to protect its drug, which accounts for about half of its revenue, but the outcome is uncertain. Although Biovail's numbers, based on historical performance, are solid enough to enable it to land on a stock screen, a little digging illuminates potential difficulties down the road that are not captured by the screens, thus serving as a nice reminder that stock screening is only part of the security-selection process and that investors need to do their homework when dealing with portfolios that only have a few names in them. I'd say the outcome is no longer particularly uncertain - BVF is almost certainly going to lose, in which case you have to look at what its continued earnings are going to be. May still be a great contrarian buy - but you can't tell that by looking at its 2006 numbers and projections. Peter